Articles Tagged with Boston Xarelto injury attorney

by

A man from Florida has filed a new Xarelto injury lawsuit against Janssen Pharmaceuticals (a division of Johnson & Johnson, which is the U.S. marketing partner of Xarelto) and Bayer A.G. which is the German pharmaceutical giant that manufactures the medication. As part of this lawsuit, he is claiming negligent manufacture of a defective drug, among several other related claims.

perscription-drug-case-1156714-mThe lawsuit was filed in a United States District Court and technically has several more named defendants than listed above because each of these other companies have several wholly owned subsidiaries that were involved in the manufacture and marketing of Xarelto according to a recent news article from the Louisiana Record. Continue reading

by

A recent article from Medpage Today looks at new uses being proposed for a class of medications know as new oral anticoagulants (NOACs).  This is a fairly new class of medications that includes Xarelto, Eliquis, Pradaxa, and Savaysa.  These medications were designed primary to treat patients who suffer from a serious medical condition know as atrial fibrillation (Afib).

perscription-drugs-2-1160103-m-300x225As you have probably heard actor Kevin Nealon tell you during a commercial break, Afib is medical condition classified as a irregular heartbeat not caused by a heart valve defect.  A patient with Afib is at risk for developing blood clots that can cause serious and often deadly problems.  They can block the flow of blood to the brain.  This deprives the brain of much needed oxygen and is what happens when a patient has a stroke. The loss of blood can cause death or serious brain injury that can have life long effects. Continue reading

by

Janssen, which is a division of pharmaceutical giant Johnson & Johnson, is the U.S. marketing partner of Bayer, the German drugmaker that manufactures Xarelto, and has released a report that its new oral anticoagulant (NOAC) is superior to Warfarin (Coumadin) in reducing the risk of ischemic stroke, according to a recent news feature from Cardiovascular Business.

tylenolThe company also claims that Xarelto is superior to Warfarin in reducing the risk of intracranial hemorrhage. The reason patients take a blood thinner or oral anti-coagulant such as Xarelto is because they are at significant risk of developing blood clots due to a medical condition known as atrial fibrillation (Afib).  These clots can form in various places, including deep in the veins of the legs.  If they form in the legs, it is a potentially deadly medical condition known as deep vein thrombosis (DVT).  Continue reading

by

A recent feature from CBS News examined whether Johnson & Johnson and Bayer, the makers of Xarelto, knowingly withheld certain important data for a letter to be published in the New England Journal of Medicine.

nurse-1-1158314-mThe specific claim made by lawyers for Xarelto plaintiffs in the multi-district litigation (MDL) class action lawsuit is that the defendants purposely withheld information from results published involving a Duke University analysis of drug trial results.  This information relates to a blood testing device that was not functioning property.  The device was being used to test patients who were on Warfarin (Coumadin), which is the traditional alternative to Xarelto.  Continue reading

by

There is a good chance that the millions of people watching this year’s Super Bowl will see a commercial for Xarelto. Xarelto, with a generic name rivaroxaban, is making hundreds of millions of dollars for Beyer and Janssen (a wholly owned Johnson & Johnson subsidiary), and these companies will take any chance they can get to increased sales.

untitled-1238929-mXarelto is a often called a blood thinning medication like Warfarin (Coumadin), which is its biggest competitor, but it is actually an anticoagulant. Xarelto serves the same purpose as a blood thinner, but workers differently. A blood thinner, as the name implies, thins a patient’s blood, and this makes it more difficult for blood clots to form. There is nothing wrong with clotting when we are talking about a cut that is bleeding. The human body produces platelets to form clots to stop bleeding when a laceration occurs. Continue reading

by

Xarelto has come under a lot of fire lately, as thousands of people have developed a deadly internal bleeding disorder after taking the anticoagulant, and more than 60 people have died. The basis of these claims are that the makers of Xarelto, Bayer and Janssen (a division of Johnson & Johnson), designed a defective drug and failed to adequately warn plaintiffs of a danger about which they knew or should have known.

pillsXarelto is a member a relatively new class of drugs known as New Oral Anticoagulants (NOACs), which were designed to compete with traditional blood thinning medications such as Coumadin (Warfarin). Warfarin is a blood thinner that is prescribed to many patients who suffer from a serious medical condition know as atrial fibrillation (Afib). Afib is basically an irregular heartbeat, which can lead to the formation of clots in the deep veins of the legs. If the clots break free, they can travel through the body until they puncture the lungs or cause a stroke if the blood supply to the brain is blocked. When a clot punctures a patient’s lung, this is known as a pulmonary embolism (PE). Continue reading

by

With the regular NFL season coming to close and playoffs heating up, there will be more people watching football than at any other point in the season. This will, of course, culminate with Super Bowl 50. During the Super Bowl, many will tune in for the big game and others will come just for the commercials. Super Bowl commercials are such a big draw that advertisers will pay over $10 million for a single 30-second spot.

perscription-drugs-2-1160103-mAs we have seen during the regular season, we can expect to see commercials for Xarelto, along with Pradaxa and Eliquis, and possibly Savaysa. These are all members of a new class of drugs called New Oral Anticoagulants (NOAC). They are prescribed for patients who suffer from a serious, but manageable health condition known as atrial fibrillation (Afib). Afib patients have an irregular heartbeat that causes large clots to form deep within in the veins of the legs in a condition known as deep vein thrombosis (DVT). When one of these clots breaks free where it has formed, it can travel through the bloodstream causing disastrous results. It can puncture a hole in the lungs known as a pulmonary embolism (PE) that can be deadly. The clots can also block the flow of blood to the brain, causing a stroke. Continue reading

by

Xarelto is a member of class of drugs known as New Oral Anticoagulants (NOACs). It is an alternative to traditional blood thinners such a Warfarin (Coumadin), which is often prescribed to patients who suffer from a serious medical condition known as atrial fibrillation (Afib). Afib is a medical condition classified by an irregular heartbeat that causes stroke or heart attack.

untitled-1238929-mWhile Xarelto has been shown to be effective in preventing stroke or heart attacks in Afib patients, it has a potentially deadly side effect. Thousands of Xarelto users have developed a serious internal bleeding disorder caused by the drug, and this can include intracranial bleeding. There are no warning signs or risk factors that seem to make some patients more likely than others to develop the bleeding disorders, and there is also no FDA approved reversal agent (antidote). Essentially, people come into emergency rooms with internal bleeding, and there is nothing doctors can do to save the patients. For this reason, the Xarealto related bleeding disorder is considered potentially fatal. There is an antidote for a Xarelto competitor known Pradaxa, but that antidote (Praxbind) is not approved for Xarelto victims. Continue reading

by

Xarelto, Pradaxa, and Eliquis are three of four New Oral Anticoagulants (NOACs) that are all fighting with each other and the makers of Warfarin (Coumadin) to become the market leader for medications used for the prevention of serious blood clotting disorders in patients who suffer from a medical condition known as atrial fibrillation (Afib). Afib patients have an irregular heartbeat that can cause large blood clots to form deep within the veins of the legs. These clots can break free of the veins in which they form and travel through the circulatory system to the lungs, where they can cause a deadly tear known as a pulmonary embolism (PE).

syringes-and-vial-1028452-mAs described in a recent industry feature from FiercePharma, in order to prevent these clots from forming, doctors will typically prescribe an oral medication. For many years the gold standard was Warfarin (Coumadin), and this medicine is actually a blood thinner. While it is every effective in treating Afib patients, it is not the most convenient for patients, and there are some risks. If the dose of medication is off, the patient may suffer a serious internal bleeding condition. However, the patient can monitor his or her diet closely, as certain foods affect the rate of Coumadin absorption, and he or she can have regular blood tests to make sure the dosage is correct. Continue reading

by

For several years, Pradaxa, Elliquis, and Xarelto have had the market cornered on sales of New Oral Anticoagulants (NOACs) as treatment for patients who suffer from a serious medical condition known as atrial fibrillation (Afib). NOACs are an entirely new class of drugs designed to replace conventional blood thinners, such as Coumadin (Warfarin).

money-trading-1-1415239-mHowever, Daiichi Sankyo has recently entered the market with its own NOAC product under the name Savaysa. The company has high hopes for Savaysa sales, given that it recently lost its patent for Benicar, according to a recent news article from Fierce Pharma. Benicar, which will soon be available as a generic, is responsible for around 27 percent of Daiichi sales, so this loss will hurt. The company is hoping to make up for that loss with sales of their new drug, Savaysa, but they are running into some stumbling blocks. Continue reading

Contact Information
Boston Office
1 International Pl Unit 1810
Boston, MA 02110
Phone: (617) 777-7777Fax: (617) 722-9999
Taunton Office
60 Court St
Taunton, MA 02780
Disclaimer – The settlements above are only a sample of cases represented by our office. Each case is different and the amount of a potential resolution of your case will vary considerably depending on a substantial amount of factors. Some case results were worked in conjunction with partnering law firms.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Please do not include any confidential or sensitive information in a contact form, text message, or voicemail. The contact form sends information by non-encrypted email, which is not secure. Submitting a contact form, sending a text message, making a phone call, or leaving a voicemail does not create an attorney-client relationship.

Copyright © 2024, Jeffrey Glassman Injury Lawyers
JUSTIA Law Firm Blog Design